Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 15/20 | 0.78 |
| ▸ | NPM1 | P06748 | 12/20 | 0.78 |
| ▸ | INSR | P06213 | 9/20 | 0.78 |
| ▸ | JAK2 | O60674 | 6/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16530651 | 1.00 | ALK (0.78) | ALKNPM1INSRJAK2PTK2 | |
| Trifluoroacetic Acid SCHEMBL520142 | 0.95 | ALK (0.72) | ALKNPM1INSRJAK2PTK2 | |
| SCHEMBL16530863 | 0.90 | ALK (0.71) | ALKNPM1INSRJAK2PTK2 | |
| SCHEMBL16530864 | 0.90 | ALK (0.71) | ALKNPM1INSRJAK2PTK2 | |
| SCHEMBL520143 | 0.88 | ALK (0.63) | ALKNPM1INSRJAK2PTK2 | |
| SCHEMBL520990 | 0.88 | ALK (1.00) | ALKNPM1INSRJAK2PTK2 | |
| SCHEMBL520989 | 0.88 | ALK (1.00) | ALKNPM1INSRJAK2PTK2 | |
| SCHEMBL520144 | 0.87 | ALK (0.60) | ALKNPM1INSRJAK2PTK2 | |
| Trifluoroacetic Acid SCHEMBL519873 | 0.86 | ALK (0.67) | ALKNPM1INSRJAK2PTK2 | |
| SCHEMBL521087 | 0.84 | JAK2 (0.85) | ALKNPM1INSRJAK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | claimed |